Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Tyligand Bio Files Hong Kong IPO with Phase II KRAS G12D Inhibitor TSN1611

Fineline Cube Jan 30, 2026
Company Deals

Genhouse Bio Files Hong Kong IPO with Phase II SHP2 Inhibitor GH21

Fineline Cube Jan 30, 2026
Company Deals

CSPC Pharma Signs $18.5B AstraZeneca Deal for Weight Management Portfolio

Fineline Cube Jan 30, 2026
Company Deals

Fosun Pharma Licenses HPV DNA Drug VGX-3100 from ApolloBio for Greater China

Fineline Cube Jan 29, 2026
Company Deals

Kanghua to Acquire NanoRibo in Phased Deal for mRNA Platform

Fineline Cube Jan 29, 2026
Policy / Regulatory

FDA Removes Suicide Warnings from GLP‑1 Drugs After Investigation Finds No Causal Link

Fineline Cube Jan 28, 2026
Company Drug

China Medical’s Opzelura Cream Gets NMPA Approval for Vitiligo

Fineline Cube Jan 30, 2026
Company Drug

Zhaoke Ophthalmology’s Yuvezzi Gets FDA Nod for Presbyopia

Fineline Cube Jan 30, 2026
Company Drug

CMS Secures NMPA Approval for Clinical Trials of TYK2 Inhibitor CMS-D001 and GnRH Antagonist CMS-D002

Fineline Cube Feb 8, 2024

China Medical System Holdings Ltd (CMS, HKG: 0867) has announced that it has received clinical...

Company Drug

Evopoint Biosciences Enrolls First Patient in Phase III Trial for Gout Drug XNW3009

Fineline Cube Feb 8, 2024

Suzhou-based Evopoint Biosciences Co., Ltd. has announced the enrollment of its first patient in a...

Company Drug

ChinaGene Secures CDE Approval for ZVS101e Gene Therapy Targeting Retinitis Pigmentosa

Fineline Cube Feb 8, 2024

Beijing-based ChinaGene Technology Co., Ltd. has announced that it has received tacit clinical approval from...

Company Deals

Yantai Dongcheng Acquires Full Rights to Alfatide II, Targeting Diagnostic and Therapeutic Applications

Fineline Cube Feb 8, 2024

Yantai Dongcheng Pharmaceutical Group Co., Ltd. (SHE: 002675) has announced its acquisition of all rights...

Company Drug

Nanjing Zenshine’s ZX-7101A NDA Accepted by NMPA for Uncomplicated Influenza Treatment

Fineline Cube Feb 8, 2024

Nanjing Zenshine Pharmaceuticals Co., Ltd., a China-based small molecule drug developer, has announced that the...

Company

Gilead’s 2023 Flat Sales Reflect Stagnation and COVID-19 Demand Decline

Fineline Cube Feb 7, 2024

Gilead Sciences Inc. (NASDAQ: GILD) has reported a stagnant performance for the year 2023, with...

Company

Astellas Pharma Inc. Reports 2.1% YOY Growth in Q1-Q3 Fiscal 2023 Revenues

Fineline Cube Feb 7, 2024

Tokyo-based pharmaceutical company Astellas Pharma Inc., (TYO: 4503) has announced financial results for the first...

Company

Gilead’s 2023 Stagnation Foresees Flat 2024 Sales as Veklury Revenues Dwindle

Fineline Cube Feb 7, 2024

Gilead Sciences (NASDAQ: GILD) has reported a stagnant performance for 2023, with product sales remaining...

Company

Amgen’s Q4 2023 Results Showcase 9% YOY Growth, 18 Drugs Hit Record Sales

Fineline Cube Feb 7, 2024

Biopharmaceutical giant Amgen (NASDAQ: AMGN) has reported its financial results for Q4 2023, announcing annual...

Policy / Regulatory

Medical Institutions Directed to Adhere to ‘Six Should Do’s’ and ‘Six Prohibited Behaviors’ for Academic Lectures

Fineline Cube Feb 7, 2024

Medical institutions have reportedly been circulated with a “Notice on Issuing Work Tips for Medical...

Policy / Regulatory

China Proposes Market-Oriented Pricing for Innovative Drugs to Boost High-Quality Development

Fineline Cube Feb 7, 2024

The National Healthcare Security Administration (NHSA) has unveiled a draft Notification on “Establishing a Price...

Company

Eli Lilly’s 2023 Revenue Soars on Metabolism Drugs, Anticipates Further Growth in 2024

Fineline Cube Feb 7, 2024

Eli Lilly and Company (NYSE: LLY) reported a robust 2023 financial performance with a 20%...

Company Drug

Jiangsu Hengrui Receives NMPA Approval for Phase II Study of GLP-1 Agonist for Weight Loss

Fineline Cube Feb 7, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...

Company

Innovent Biologics Posts 65% YOY Growth in Q4 2023 with Over RMB 1.6 Billion in Sales

Fineline Cube Feb 7, 2024

Chinese biopharmaceutical company Innovent Biologics Inc., (HKG: 1801) has reported impressive quarterly sales figures, announcing...

Company Drug

Shanghai Procurement Platform Offers Price Cut Leeway to Escape ‘High-Priced Drugs’ Tag

Fineline Cube Feb 7, 2024

Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) platform has announced a significant policy shift regarding non-winning...

Company Drug

BioNTech and Duality’s DB-1305 Earns Fast-Track Status for Platinum-Resistant Cancers

Fineline Cube Feb 7, 2024

German biotechnology company BioNTech SE (NASDAQ: BNTC) and its partner Duality Biologics (Suzhou) Co., Ltd...

Policy / Regulatory

NMPA Reports Record 61 Innovative Medical Device Approvals in 2023

Fineline Cube Feb 6, 2024

The National Medical Products Administration (NMPA) has released its 2023 medical device filings work report,...

Company Deals

Novartis to Acquire MorphoSys for €2.7 Billion in Strategic Oncology Expansion

Fineline Cube Feb 6, 2024

Switzerland-based Novartis (NYSE: NVS) has announced a voluntary public takeover offer to acquire Germany-based biopharmaceutical...

Company Deals

Bayer Partners with TetraScience to Enhance Data Management in Product Development

Fineline Cube Feb 6, 2024

Germany-based Bayer (ETR: BAYN) has announced a partnership with data management firm TetraScience to collect...

Company Deals

Zhejiang Anglikang Enters R&D Cooperation Agreement with Affinity Biopharmaceutical

Fineline Cube Feb 6, 2024

China-based Zhejiang Anglikang Pharmaceutical Co., Ltd. (SHE: 002940) has entered into a research and development...

Posts pagination

1 … 353 354 355 … 617

Recent updates

  • China Medical’s Opzelura Cream Gets NMPA Approval for Vitiligo
  • Zhaoke Ophthalmology’s Yuvezzi Gets FDA Nod for Presbyopia
  • CSPC’s SYS 6055 CAR-T Gets NMPA Nod for Lymphoma Trials
  • AstraZeneca Commits $14.4B China Investment in Cell Therapy Push
  • Ascletis ASC40 Phase III Success in Acne Vulgaris
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

China Medical’s Opzelura Cream Gets NMPA Approval for Vitiligo

Company Drug

Zhaoke Ophthalmology’s Yuvezzi Gets FDA Nod for Presbyopia

Company Drug

CSPC’s SYS 6055 CAR-T Gets NMPA Nod for Lymphoma Trials

Company

AstraZeneca Commits $14.4B China Investment in Cell Therapy Push

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.